Latest Shareholder Meeting News

Pinnacle Minerals has advanced its strategic pivot to North American critical minerals exploration, initiating fieldwork across multiple US projects and securing a strong cash position of approximately A$2.8 million.

Nelson Resources has consolidated the historic Gold Point mining district in Nevada with a 90% stake, unveiling high-grade gold-silver potential and preparing for maiden drilling in Q2 2026. Meanwhile, a strategic partnership with MEGA Resources advances a major drilling program at the Yarri Gold Project in Western Australia.

Octava Minerals has amended its acquisition terms for the Byro REE Project, extending the deadline and replacing a share grant with performance rights tied to project milestones.

A shareholder dispute over Humm Group's handling of competing acquisition bids has escalated to the Takeovers Panel, spotlighting governance and transparency concerns ahead of a pivotal shareholder meeting.

Cyprium Metals has raised A$41 million through an oversubscribed equity placement and entitlement offer to accelerate exploration and production growth at its flagship Nifty Copper Complex and regional projects.

Global Uranium and Enrichment Limited has finalised the share and option scheme considerations for its acquisition by Snow Lake Resources, with directors backing the deal ahead of the upcoming shareholder vote.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

Sunstone Metals is seeking shareholder approval for a 30-for-1 share consolidation aimed at simplifying its capital structure and enhancing investor appeal. The move follows a recent placement that left the company with over 7 billion securities on issue.

Energy Fuels Inc. has announced a binding agreement to acquire Australian Strategic Materials Ltd (ASM) in a deal valuing ASM at approximately A$447 million, offering shareholders a 121% premium. The acquisition aims to establish a vertically integrated Western rare earths supply chain, aligning with critical minerals strategies between the US and Australia.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Askari Metals has responded to an ASX query regarding an inadvertent breach of Listing Rule 10.11 after issuing securities to a related party without prior shareholder approval during a recent rights issue. The company outlines the circumstances and its planned remedial actions.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.